[
  {
    "ts": null,
    "headline": "Gilead Sciences, Inc. (GILD)’s Breast Cancer Study Success Drives Investor Optimism Amid Broader Market Slump",
    "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) has revealed encouraging results from its ASCENT-03 clinical trial, showcasing a major breakthrough in treating metastatic triple-negative breast cancer (mTNBC). Trodelvy (sacituzumab govitecan-hziy) demonstrated a significant and meaningful improvement in progression-free survival compared to chemotherapy in first-line mTNBC patients who cannot receive immunotherapy. This marks the first substantial progress in over […]",
    "url": "https://finnhub.io/api/news?id=baaa1d76c49e3fa327470360cfbd4b1819dbe395b7a1c877cec2d18ef3ba815c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748098970,
      "headline": "Gilead Sciences, Inc. (GILD)’s Breast Cancer Study Success Drives Investor Optimism Amid Broader Market Slump",
      "id": 134694414,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) has revealed encouraging results from its ASCENT-03 clinical trial, showcasing a major breakthrough in treating metastatic triple-negative breast cancer (mTNBC). Trodelvy (sacituzumab govitecan-hziy) demonstrated a significant and meaningful improvement in progression-free survival compared to chemotherapy in first-line mTNBC patients who cannot receive immunotherapy. This marks the first substantial progress in over […]",
      "url": "https://finnhub.io/api/news?id=baaa1d76c49e3fa327470360cfbd4b1819dbe395b7a1c877cec2d18ef3ba815c"
    }
  },
  {
    "ts": null,
    "headline": "Gilead announces ASCENT-03 study meets primary endpoint",
    "summary": "Gilead (GILD) announced topline results from the Phase 3 ASCENT-03 study of Trodelvy. The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival compared to chemotherapy in patients with first-line metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitors, meaning they are PD-L1 negative or are ineligible to receive immunotherapy. The safety profile of Trodelvy in the ASCE",
    "url": "https://finnhub.io/api/news?id=d65db1a14965bf167eb1d3eef44adffb13f9493d7e778fb31792d793b577da02",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748090413,
      "headline": "Gilead announces ASCENT-03 study meets primary endpoint",
      "id": 134694415,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead (GILD) announced topline results from the Phase 3 ASCENT-03 study of Trodelvy. The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival compared to chemotherapy in patients with first-line metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitors, meaning they are PD-L1 negative or are ineligible to receive immunotherapy. The safety profile of Trodelvy in the ASCE",
      "url": "https://finnhub.io/api/news?id=d65db1a14965bf167eb1d3eef44adffb13f9493d7e778fb31792d793b577da02"
    }
  }
]